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Surfactant protein C (SP-C) is an essential component for the surface tension-lowering activity of the pulmonary surfactant system. It contains
a valine-rich α helix that spans the lipid bilayer, and is one of the most hydrophobic proteins known so far. SP-C is also an essential component of
various surfactant preparations of animal origin currently used to treat neonatal respiratory distress syndrome (NRDS) in preterm infants. The
limited supply of this material and the risk of transmission of infectious agents and immunological reactions have prompted the development of
synthetic SP-C-derived peptides or recombinant humanized SP-C for inclusion in new preparations for therapeutic use. We describe herein the
recombinant production in bacterial cultures of SP-C variants containing phenylalanines instead of the palmitoylated cysteines of the native
protein, as fusions to the hydrophilic nuclease A (SN) from Staphylococcus aureus. The resulting chimerae were partially purified by affinity
chromatography and subsequently subjected to protease digestion. The SP-C forms were recovered from the digestion mixtures by organic
extraction and further purified by size exclusion chromatography. The two recombinant SP-C variants so obtained retained more than 50% α-
helical content and showed surface activity comparable to the native protein, as measured by surface spreading of lipid/protein suspensions and
from compression π–A isotherms of lipid/protein films. Compared to the protein purified from porcine lungs, the recombinant SP-C forms
improved movement of phospholipid molecules into the interface (during adsorption), or out from the interfacial film (during compression),
suggesting new possibilities to develop improved therapeutic preparations.
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Fig. 1. Comparison between sequences of SP-C from different origins and
sequence and schematic organisation of the rSP-C variants. (A) Native SP-C
sequence alignment highlighting the Cys residues in blue and Phe residues in
red. In the porcine sequence, the helical region from the NMR structure [46] is
boxed. (B) Amino acid sequences of the rSP-Cs produced in this work. (C)
Schematic organisation of the chimerical protein expressed in bacteria. 
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Surfactant-associated protein C (SP-C) together with a sec-
ond hydrophobic surfactant protein, SP-B, and phospholipids
represents the active component of the lung surfactant (LS). LS
is the surface active material present at the air–liquid interface in
the alveoli of mammalian lungs. Its role is to lower the normal
air–water surface tension, from 70 mN/m to near zero, upon
expiration, thereby preventing alveolar collapse and minimizing
the work of their expansion during inhalation [1]. Deficiency or
inactivation of LS causes pulmonary dysfunctions, the most
common being neonatal respiratory distress syndrome (NRDS),
caused by the absence of surfactant in premature infants. Re-
placement surfactants currently applied in clinical therapy are
obtained from animal lungs. However, this is an expensive and
inexact source, and levels of SP-B and SP-C in commercial
surfactant preparations vary from batch to batch and are typically
lower that in native pulmonary surfactants [2,3]. Additionally,
the potential risks of transmission of animal-derived diseases or
immunological reaction justify the need for a human-like
standardised material as a suitable alternative [4]. The possibility
to optimise artificial surfactant formulations to treat specific
diseases should also open new perspectives for the treatment of
respiratory pathologies.
Several efforts have been made in order to develop artificial
mimics of the natural surfactant by combining synthetic lipids
and peptides that correspond to segments of native SP-B and
SP-C. Tests in vitro and in animal models show that their
biophysical activity is usually superior to the one of
phospholipids alone [5]. However, production of successful,
entirely synthetic surfactant preparations has been so far
hindered by the difficulties in obtaining both surfactant proteins,
SP-B and SP-C, mainly due to their high hydrophobicity.
SP-C, one of the most hydrophobic proteins in the proteome,
is a 35-amino acid polypeptide that constitutes approximately
1% of the surfactant mass [6]. It is composed of a short N-
terminal region, palmitoylated at residues Cys-5 and Cys-6, and
followed by an α-helical hydrophobic transmembrane (TM) C-
terminal stretch made of aliphatic residues. The sequence of SP-
C is highly conserved through evolution, with predominance of
valine residues in the TM domain and only small differences
between species (Fig. 1A). It is proposed that SP-C is involved
in the formation of multilayer lipid stacks attached to the air–
liquid interface, which act as a source of reservoir of lipids
that can be reinserted into the monolayer during alveolar ex-
pansion [7]. However, detailed molecular mechanistic studies
are still missing.
Apart from the above mentioned extreme hydrophobicity,
the difficulty for obtaining artificial SP-C analogues derives
from its strong tendency to misfold and aggregate in the absence
of phospholipids [8,9]. The TM α helical fragment, represented
by 10–12 valines with intermittent Ile and Leu residues, is
capable of populating irreversibly into a fibrilar β-structure
aggregate. In aqueous solutions β-branched valines and
isoleucines display a preference toward β-strands and are
usually underrepresented in α helices. However, in lipid
environments Val and Ile residues promote helix formation[10]. In agreement with this general tendency, the α helical
polyVal-rich region of SP-C was found to convert spontane-
ously into β sheets in vitro, with an enhanced rate of α→β
transition in the presence of polar solvents and deacylation [11].
Current data emphasize a strong correlation between the loss of
helical structure of SP-C and its malfunctioning [12]. Moreover,
SP-C amyloid fibrils are found in patients with pulmonary
alveolar proteinosis [8].
The highly hydrophobic membrane proteins are generally
difficult to over-express and purify [13]. They are usually
produced in heterologous systems, as fusions with soluble
portions of bacterial proteins. The presence of detergents during
the purification is often required in order to prevent formation of
aggregates, especially at the point where the TM portion is
cleaved from its fusion. Following enzymatic cleavage, the TM
proteins are generally purified by reversed phase (RP) HPLC
[14]. Membrane proteins that do not have fibril forming
propensities can, once unfolded and precipitated, be recovered
in the presence of detergents or lipids. However, this three-step
method is not readily applicable to SP-C, since purifying the
protein by RP-HPLC bears the risk of its denaturation leading to
irreversible aggregation and complete inactivation. A method
has been published for expression and purification of
recombinant SP-C (rSPC) in Escherichia coli as a fusion to
the N-terminal portion of bacterial chloramphenicol acetyl
transferase [15]. Surfactant preparations containing this version
of rSP-C as the unique protein component have shown to be
effective for the treatment of respiratory distress [16,17].
In this report, we describe a novel approach for expression
and purification of human SP-C, based on the combination of a
successful TM protein expression strategy in bacteria with the
established organic extraction protocol typically used for
separation of native SP-C from LS mixtures. This new
procedure is very effective for preserving the native helical
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producing protein forms with high surface activity in
reasonable amounts. We have modified the SP-C sequence
by Cys5Phe and Cys6Phe substitutions. The rationale behind
these changes is that the naturally occurring palmitoylation of
the two Cys residues cannot be achieved through bacterial
protein expression. The modified protein remains very close to
the native sequence present in some animal surfactants (Fig.
1). Moreover, the same Cys→Phe replacements are present in
the SP-C analogue used in a successful synthetic surfactant
preparation [18]. Detailed analysis of the highly pure rSP-C
forms produced in this work reveals a slightly improved
surface activity when compared to the native SP-C obtained
from animal lungs.
2. Materials and methods
2.1. Protein expression and purification
Construction of plasmids encoding the His-tagged chimerical protein (SN/
GpA) has been described [19]. The glycophorin A (GpA) sequence in the
original plasmid was replaced by a PCR-amplified sequence of human SP-C
(generous gift from Dr. Joanna Floros, University of Pennsylvania at
Hershey), using ApaI/BamHI restriction sites. The N-terminal His-tag, the
optimised thrombin digestion site, and all point mutations in the wild type
sequence of SP-C were introduced by site-directed mutagenesis using the
QuikChange kit from Stratagene (La Jolla, California) and verified by DNA
sequencing.
The expression of the fusion protein was performed as described earlier [20].
Briefly, a 10-mL overnight culture of BL21 (DE3) pLys (Novagen, Madison,
WI) cells transformed with the corresponding vector was inoculated into 1 L of
LB medium and grown at 37 °C until the OD600 reached 0.6. IPTG (1 mM) was
added for induction and the culture was grown for additional 3 h. The cells were
harvested by centrifugation at 3800 g for 10 min in a Sorval centrifuge and
resuspended in resuspension buffer (10 mM Tris HCl pH 7.9, 1 mM EDTA,
0.01 M PMSF). Pellets were frozen until use. In order to break the cellular
membranes, the pellets were freeze-thawed three times, sonicated and added to
the same volume of TBS 1% lauroyl sarcosine detergent. This mixture was
centrifuged at 18,000 g for 10 min. The fusion protein was purified from the
supernatant via immobilized metal affinity chromatography. An ÄKTA purifier
liquid chromatography system (Amersham Bioscience) was used with a His-
Trap column filled with nickel containing resin. The buffers for chimerical
protein purifications were the following: equilibration buffer, TBS 0.5% lauroyl
sarcosine; wash buffer, TBS 0.2% lauroyl sarcosine 10 mM imidazol; andFig. 2. SDS-PAGE analyses of over-expressed chimeric proteins, thrombin digestion
stained 12% SDS-PAGE of aliquots taken during the purification of chimeric protein
bacterial lysate; lane 4, nickel column flow through; lane 5, eluate form nickel column
blue-stained 15% acrylamide tricine gel loaded with an aliquot of the SN/SP-C chim
rSP-Cs (rSP-C, lane 2 and rGP/SP-C, lane 3) organically extracted were resolved onelution buffer, TBS 0.2% lauroyl sarcosine 500 mM imidazol. The eluted protein
was dialysed to remove imidazol and finally concentrated by using an Amicon
concentrator with YM10 ultra-filtration membrane (Milipore, Bedford MA) 5–6
times. Generally, 4 mg of the fusion protein were obtained per 1 L of LB
medium.
2.2. Thrombin digestion
A thrombin cleavage site (LVPR↓GP), introduced between SN and SP-C,
allowed the proteolysis of the fusion protein. A glycine-rich ‘kinker’ next to the
thrombin cleavage site was introduced to improve the cleavage efficiency [21].
Thrombin (Novagen) digestion trials were performed before each large-scale
digestion. Usually, 10 U of thrombin were required for digestion of 1 mg rSP-C
and 1 U of thrombin was needed for 1 mg of rGP/SP-C. Thrombin digestions
were performed at 21 °C in the buffer recommended by the supplier, with
shaking at 550 rpm in Eppendorf thermomixer. The reactions were concentrated
again using a cell concentrator with membranes of 1 kDa molecular cut off.
Aliquots taken from the digestion reaction mixture were applied to tris–tricine
gels in order to monitor the appearance of the bands corresponding to the
Staphylococcal nuclease (18.5 kDa) and rSP-C (3.9 kDa) (Fig. 2B).
2.3. Organic extraction
An organic extraction of the protein solution was performed according to the
protocol of Bligh and Dyer [22] for lipid extraction. Shortly, two volumes of
methanol and one volume of chloroform were added to the protein mixture,
which was vortexed and incubated at 37 °C. After addition of one more volume
of chloroform and one of water, the mixture was vortexed and centrifuged at
550×g/5 min. The lower, organic, phase was collected and two volumes of
chloroform were added two more times to the aqueous phase in order to increase
protein recovery. All organic phases were stored in glass bottles at −20 °C. The
organic extract was concentrated to approximately 2 mL prior to application to
the lipophilic column. Protein concentration was performed in the presence of
egg yolk PC (Avanti Polar Lipids, Alabaster, AL) at a 1:5 (w:w) ratio in a rota-
vaporizer apparatus.
2.4. Sephadex LH-20 lipophilic size exclusion chromatography
In order to eliminate components other than SP-C that could have co-purified
in the organic phase, the organic extraction was applied to a Sephadex LH-20
column (Amersham Biosciences). This column is used for lipid separation and is
adapted to the use with organic solvents. Proteins and lipids are eluted from the
column by a chlorofom:metanol (2:1, v:v) eluting system. Fractions were
collected and absorbance at 240 and 280 nm was recorded on a spectrophotom-
eter. Absorbance peaks were pooled and loaded on SDS-PAGE and subsequently
analyzed for their amino acid content and by mass spectrometry.and organically extracted native and rSP-C. (A) Representative Coomassie blue-
s. Lane 1, molecular markers; lane 2, whole cell extract; lane 3, supernatant of
. The SN/SP-C chimera is marked with an arrowhead to the right. (B) Coomassie
era after (lane 2) and before thrombin digestion (lane 3). (C) Native (lane 1) and
a 16% acrylamide SDS-PAGE stained with Coomassie blue.
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For determination of the molecular masses, 0.85 μL of the of peptide
dissolved in chloroform:methanol (2:1, v:v) were spotted onto a MALDI-TOF
sample holder and allowed to dry at room temperature. An equal volume of a
saturated solution of sinapinic acid (3,5-dimethoxy-4-hydroxycinnamic acid)
(Sigma) saturated in 70% acetonitrile containing 0.1% TFA was added, let dry,
and analyzed with an Applied Biosystems Voyager-DE Pro MALDI-TOF mass
spectrometer, operated in delayed extraction and linear or reflector modes. The
mass calibration standard in linear mode consisted of a mixture of the following
proteins, whose calculated isotope-averaged molecular masses in Daltons are
given between brackets: bovine insulin (5734.6), E. coli thioredoxin (11674.5),
horse apomyoglobin (16952.6). For reflector calibration, a tryptic peptide
mixture of Cratylia floribunda seed lectin (SwissProt accession code P81517)
prepared and previously characterised in our laboratory was used.
2.6. Circular dichroism
To prepare the samples for CD measurements, the purified protein (50 μg) in
chloroform:methanol solutions was mixed with lysophosphatidylcholine (LPC)
or DPPC:POPG (7:3) at a protein: lipid ratio of 1:5 (w:w), dried under a stream
of N2 and then under vacuum for 2 h. The resulting dried films were hydrated by
addition of 0.5 mL of 5 mM Tris buffer (pH 7) containing 150 mM NaCl with
intermittent vortexing at room temperature for LPC micelles, or at 55 °C for
DPPC:POPG vesicles. The suspensions were then sonicated during 1 min. CD
spectra were obtained on a Jasco J-810 CD spectropolarimeter. Quartz cells of
1 mm optical path were used to record spectra at a scanning speed of 50 nm/min.
Generally, 15 scans were accumulated and averaged, subjected to noise
reduction and corresponding blanks subtracted. Data analysis was performed
with the help of the CDPro software package, which contains three commonly
used programs: SELCON3, CONTIN/LL and CDSSTR [23,24]. This software
allows the use of different reference sets of proteins, including 13 membrane
proteins (SMP50), to increase the reliability of the analysis.
2.7. SDS-PAGE
Fusion proteins and protein samples obtained after organic extraction or
eluted from the Sephadex column were analyzed onto 16% SDS-PAGE. The SP-
C peptide samples were first evaporated under Nitrogen gas, resuspended in the
loading buffer, boiled 5 min at 95 °C and applied to the gel. After running, gels
were fixed, stained with Coomassie blue stain and distained. In order to resolve
small molecular mass peptides generated after thrombin digestion, the samples
were loaded on tricine 15% acrylamide gel. Tricine gels were processed
identically as SDS-PAGE gels.
2.8. Interfacial adsorption
Adsorption π–t kinetics for the formation of phospholipids films as
promoted by native and recombinant forms of SP-C, were monitored on a
Wilhemy surface balance (Nima, Coventry, UK) equipped with a minitrough
(15 cm2 of surface, 5 mL volume of sub-phase) and using aWhatman N° 1 paper
dipping plate attached to the pressure transducer. Hundred μg of a mixture of
DPPC:POPG (7:3, w:w) containing 0, 2, 5 or 10% protein (w/w) were
reconstituted in 100 μL of 5 mM Tris buffer pH 7.0 containing 150 mM NaCl.
To start acquisition of the π–t adsorption isotherms, 10 μL of this suspension
were deposited directly and allowed to spread on top of the surface of the
balance and film formation was monitored following the changes in surface
pressure with time. Experiments were performed at 25 °C and repeated at least
three times with two different samples for each protein.
2.9. π–A compression isotherms
Monolayers of lipid (DPPC:DPPG, 7:3, w/w) or lipid/peptide binary
systems were made by spreading a small volume of a concentrated lipid or lipid/
peptide solution in chloroform:methanol (3:1, v/v) at the surface of a 5 mM Tris
buffered sub-phase, pH 7, containing 150 mM NaCl. These monolayers were
prepared as previously described [25], in a thermostatic (25 °C) Langmuir–Blodgett trough (NIMA Technologies, Coventry, United Kingdom) equipped
with a ribbon barrier to minimize film leakage during compression. Sub-phases
were prepared with double distilled water (the second distillation performed in
the presence of potassium permanganate). After spreading the sample on top of
the sub-phase, the organic solvent was allowed to evaporate for 10 min before
starting compression. The total area of the interface was 225 cm2 and the
monolayer was compressed at 65 cm2/min, while changes in surface pressure
were recorded and plotted against the area occupied per phospholipid molecule.
3. Results
3.1. Over-expression and digestion of chimeric proteins
rSP-C is based on the primary sequence of human SP-C
(Fig. 1). Two critical issues had to be considered to define the
expression and purification strategy of this protein: the hydro-
phobicity conferred by the polyVal stretch and the palmitoyla-
tion at Cys-5 and Cys-6, which represents an insuperable
challenge for the bacterial expressionmachinery. The high hydro-
phobicity was overcome by making a fusion with the hydrophilic
nuclease A (SN) from Staphylococcus aureus (SN/SP-C, see
Materials andmethods). An optimised thrombin cleavage site [21]
is introduced between the SN and the SP-C sequence to allow
removal of the nuclease moiety (Fig. 1C). In order to prevent
possible dimer formation via disulphide bonds in the absence of
palmitic chains we introduced a double C5C6→F5F6 mutation
[26]. Phenylalanine residues were chosen because: (i) they
represent a native surrogate to the missing Cys-6 in the native SP-
C of some animals (Fig. 1A), (ii) they have high propensity to
partition into the membrane interface [27], and iii) the Cys→Phe
substitutions were shown not to affect the activity of the SP-C
protein [18]. The fusion is preceded by a His-tag to enable its
purification through nickel-agarose affinity chromatography. The
gels in Fig. 2 show that the nuclease fusion proteins can be
expressed to high levels and partially purified on a Ni-agarose
resin (Fig. 2A), following which the nuclease moiety is removed
by specific digestion with thrombin. The two major protein bands
emerging after cleavage correspond to the nuclease and the rSP-C
moieties, respectively (Fig. 2B). The lower intensity of the rSP-C
(Fig. 2B, lane 3, bottom band) compared to the nuclease moiety
(top band) results from the six times lowermolecular weight of the
former. Importantly, only less than 10% of the total SN/SP-C
fusion proteins are expressed as inclusion bodies, as estimated
from Coomassie-stained gels (not shown). The digestion with
thrombin yields a variant of SP-Cwith two additional amino acids
at the N-terminus, namely glycine and proline (rGP/SP-C, Fig. 1,
panels B and C). A deletion of these two residues rendered a
chimera that was still susceptible to thrombin digestion, although
with a significantly decreased efficiency. The two variants were
analyzed in parallel. During both, the initial purification step and
the enzymatic cleavage of the nuclease moiety, the presence of
detergents is essential in order to dissolve the cellular membrane,
where a large part of the fusion protein is localised, and, most
important, to prevent aggregation of the rSP-C. Therefore, to
maintain the chimera in an aqueous-detergent environment, we
optimised the initial purification step and thrombin digestion.
Experimental parameters investigated included: growth media,
concentration of inducer (IPTG), size of culture batch, detergent
Fig. 3. Purification of rSP-Cs by Sephadex LH20. (A) LH 20 chromatographic
analysis of organic extracts. Absorbance at 240 (black line) and 280 (grey line)
nm was monitored. (B) Coomassie blue stained SDS-PAGE analysis of
increasing aliquots of the initial peak (lanes 1–3) and two aliquots of the distal
peak (lanes 4 and 5). Lane 6 was loaded with 15 μg of native SP-C. Size markers
are indicated on the left. 
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sonication, time and temperature (data not shown). The best
results were obtained with an initial membrane pelleting, three
freeze–thaw cycles followed by sonication and subsequent
addition of the same volume of a buffered solution containing
1% lauroyl sarcosine detergent. This mixture was centrifuged and
the fusion protein was purified from the supernatant via
immobilized-metal affinity chromatography. Thrombin digestion
was performed in the presence of the same detergent.
3.2. Extraction and purification
The highly hydrophobic nature of SP-C was used to separate
rSP-C from the rest of the thrombin reaction mixture.
Recombinant SP-Cs are expected to partition into the organic
phase once the thrombin reaction mixture is subjected to organic
extraction, whereas the hydrophilic nuclease moiety and
thrombin would remain in the water-soluble phase. In this way,
passing from a detergent-rich environment to an organic solution,
the recombinant protein is likely to maintain its helicity, a crucial
feature for its activity. Together with the rSP-C separation,
through the organic extraction procedure we eliminate detergent
molecules that partition into the organic solvent–water interface.
In order to study the electrophoretic mobility of the recombinant
polypeptides and roughly estimate the amount of protein, an SDS-
PAGE analysis was performed. Fig. 2C shows aliquots of the
organic phase bearing rSP-C (lane 2) and rGP/SP-C (lane 3)
applied to the SDS-PAGE and compared with a known amount of
the native protein, isolated from porcine lungs (lane 1). In
agreement with previous SDS-PAGE analysis of SP-C [28,29],
native and recombinant peptides run as smeared bands with
identical electrophoretic mobility, corresponding to an apparent
molecular weight of ∼6 kDa.
The final purification step involves separation of rSP-C from
components that could have co-isolated in the organic phase, by
using a lipophilic Sephadex LH-20 resin. This size exclusion
chromatography resin is resistant to organic solvents and has
been widely used for lipid–lipid and protein–lipid separations
[29,30]. Organic extractions of the natural lung surfactants are
subjected to this chromatographic procedure in order to separate
the lipid fraction from surfactant proteins (SP-B and SP-C).
Large-scale extractions yielded large volumes of extract, there-
fore a concentration step was necessary to minimize the sample
volume loaded onto the chromatography column. In order to
prevent protein self-aggregation and precipitation, we concen-
trated the rSP-C organic-extracted solution, in the presence of
egg yolk phosphatidylcholine (PC) added at 1:5 protein:lipid
ratio (w:w), in a rota-vaporizer. The concentrated extract was
loaded onto a chloroform:methanol (2:1, v:v)-equilibrated LH-
20 column and eluted using the same solvent system. The eluted
fractions were measured for their absorbance at 240 and 280 nm
(Fig. 3A). The rSP-C peak was later followed by the presence of
a band at the expected migration position on SDS-PAGE of the
pooled peak fractions (Fig. 3B).
The mass spectra of the purified peptides were in agreement
with the expected molecular masses of 3783 and 3938 Da, for
rSP-C and rGP/SP-C, respectively (Fig. 4). The identity of theserecombinant surfactant peptides was further confirmed by
amino acid sequencing (data not shown) and their precise
concentration was established by amino acid analysis. The final
yield obtained for purified rSP-C was up to 0.5 mg per liter of
bacterial culture.
3.3. Secondary structure determination
In order to test whether the rSP-Cs retained their helical
conformation after the purification process, their secondary
structure was evaluated by circular dichroism (CD) spectroscopy
(Fig. 5). CD spectra in the far UV region, between 250 and
190 nm, were used to estimate the contributions of different
secondary structures to the conformation of the proteins. We
studied the structure of recombinant and native SP-Cs in LPC
micelles (Fig. 5A) and lipid (DPPC:POPG, 7:3 w/w) vesicles
(Fig. 5B), to mimic the natural environment of SP-C. As seen in
Fig. 5, all proteins exhibited CD spectral features consistent with
a predominantly α-helical conformation, as judged by the
presence of two peaks at 208 and 222 nm. The spectra of rGP/
SP-C and the native SP-C were quantitatively comparable and
similar to those reported in the literature [29,31], while rSP-C
exhibited a somewhat higher content of α-helix. To obtain a
more detailed structural description, the CD spectra were
analyzed by using the CDPro suite of programs (SELCON3,
Fig. 4. Mass spectra of rSP-Cs purified on Sephadex LH20. The content of the
first peak in the chromatograms of Fig. 3 were analyzed by MALDI-TOF-MS as
described in Materials and methods. rGP/SP-C and rSP-C spectra are shown in
panels A and B, respectively.
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obtained with the three programs using a reference set of
proteins that includes several membrane proteins, which
supports the reliability of the structure estimation. Table 1
summarises the relative proportions of different types of
secondary structure obtained, although the values should be
taken with caution because for small proteins flexibility mayFig. 5. Circular dichroism spectra of native and recombinant SP-Cs reconstituted in
rSP-C (dashed line) spectra were recorded in the presence of LPC micelles (A) and D
(see Materials and methods).reduce the dichroic properties of the C_O bond. The increased
α-helical content of rSP-C relative to the native SP-C is con-
sistent with an N-terminal extension of the helical region of the
protein, as observed in recent NMR structures of a recombinant
SP-C mutant and a synthetic SP-C analogue, both bearing
phenylalanine instead of cysteine residues [26,32]. Thus, NOE-
data supported an extended α-helix between residues 11 and 34
in the native protein [12], between residues 5 and 34 in the
recombinant variant [26], or between residues 7 and 34 in the
synthetic SP-C analogue [32].
3.4. Interfacial adsorption activity
Fig. 6 illustrates the ability of recombinant SP-Cs to promote
formation of surface-active interfacial films from lipid/protein
suspensions, in comparison with the activity of native SP-C
purified from porcine lungs. We choose the mixture of DPPC
and POPG in proportion 7:3 (w:w) as a model system because it
is a simple lipid mixture widely used to mimic roughly the lipid
composition of LS. Increasing amounts of protein were added to
the same amount of lipids in order to monitor the protein effect.
As shown in Fig. 6, in the absence of proteins the lipids hardly
adsorbed into the interface. In contrast, in the presence of native
SP-C, film formation occurs rapidly depending on the protein
concentration, to reach maximal equilibrium pressures that were
slightly lower than the expected equilibrium pressure for an
interface fully saturated with phospholipids during the time
assayed. The amount and concentration of lipid or lipid/protein
material used in these assays was chosen to detect potential
quantitative differences in the surface activity of the different
protein preparations. When amounts higher than 10 μg, or
concentrations higher 1 mg/mL, of phospholipids were used,
preparations containing native SP-C were able to reach
equilibrium surface pressures close to 45–48 mN/m in a few
minutes (not shown). Under the limiting amounts of material
used in the present adsorption experiments, rSP-C and rGP/SP-
C exhibited slightly, but consistently, better activity, with the
mixtures containing the highest amount of protein reachingsurfactant-mimetic media. Native SP-C (solid line), rGP/SP-C (dotted line) and
PPC:POPG (7:3) vesicles (B). In all samples, 25 μM of proteins were analyzed
Table 1
Secondary structure of the native and recombinant SP-C proteins after analysis of the CD spectra using the CDPro package [23,24]
Protein b % Secondary structure a
LPC DPPC:POPG
H S t r H S t r
Av S.D. Av S.D. Av S.D. Av S.D. Av S.D. Av S.D. Av S.D. Av S.D.
SP-C 51 3 7 2 21 2 21 5 49 5 10 3 19 2 22 6
rGP/SP-C 52 4 7 3 22 4 19 6 47 4 8 2 22 1 23 3
rSP-C 75 9 7 3 9 3 9 5 72 8 8 2 8 4 12 5
a H: accumulated value for regular and distorted α-helix, S: accumulated value for regular and distorted β-strand, t: turn, r: random, as defined by the standard output
of CDPro. Av is the average of the results obtained with CDSSTR, CONTILL and SELCON3, and S.D. is the standard deviation.
b All measurements were performed at 25 μM concentration of the corresponding protein.
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suggests an optimal interaction of the recombinant peptides
with the phospholipids. Optimal adsorption activities have been
previously reported for other rSP-C forms expressed in bacteria
using different strategies [15,33,34], but a quantitative compar-
ison of their activity with respect to native SP-C under limiting
conditions was not been performed.Fig. 6. Interfacial adsorption activity. The panels show the π–t adsorption
isotherms for interfacial film formation after deposition of 10 μL of 10 mg/mL
DPPC:POPG (7:3) suspension in the absence or presence of 2, 5 or 10% native
SP-C (A), rGP/SP-C (B) or rSP-C (C).3.5. Compression isotherms
To get a deeper insight into the apparently higher surface
activity of the recombinant forms of SP-C produced here, we
have analyzed in detail the π–A compression isotherms of
DPPC/dipalmitoyl-phosphatidylglycerol (DPPG) (7:3, w/w)
films in the absence and in the presence of different proportions
of the native porcine SP-C or the recombinant rSP-C or rGP/SP-
C forms. For these experiments we have used only disaturated
lipids to preserve the main features of the isotherm, including
the conspicuous liquid-expanded (LE)-to-liquid-condensed
(LC) transition plateau, which occurs at around 10 mN/m in
either DPPC or DPPG films at 25 °C. Fig. 7 shows that
progressive proportions of the three proteins induce a shift of
the isotherms towards increasing molecular area, as a result of
the space taken by the protein molecules. Overall, recombinant
proteins produce larger expansions of the isotherm than the
native palmitoylated protein. This observation indicates that the
structural changes introduced at the N-terminal segment of the
recombinant forms with respect to native SP-C have significant
consequences on the disposition and/or orientation of the
protein at the interface. Lipid–protein films containing the three
analyzed proteins produce isotherms that converge upon
compression with the isotherms of the pure lipid monolayers
at similar pressures of around 50 mN/m. This feature is con-
sistent with a similar stability of the three proteins at the inter-
face, from where they are squeezed-out at similar compression
states. It is remarkable that the compression-driven exclusion of
the three proteins is accompanied by the squeeze-out of some
lipid molecules, as deduced from the progressive shift of the
isotherm to smaller areas at pressures higher than 50 mN/m
[35]. The extent of such a shift increases progressively with the
amount of protein present. Again, the recombinant SP-C forms
produce larger shifts of the isotherms than native SP-C when
lipid–protein films are compressed beyond 50 mN/m. In Fig. 8,
we have plotted the percentage of area removed from the
interface in lipid/protein films compressed to 60 mN/m – a
pressure well above the squeeze-out plateau of the isotherms –
with respect to the area occupied by a pure lipid film at the same
pressure, as a function of the molar proportion of protein in the
films. Assuming that all protein molecules were squeezed-out
from the interface upon compression up to 60 mN/m, the slope
of these plots gives an estimate of the molar lipid/protein ratio
Fig. 7. Compression π–A isotherms of lipid and lipid/protein films. Films of DPPC/DPPG (7:3, w/w) in the absence (bold lines) or presence of 2% (circles), 5%
(triangles) or 10% (squares) of the SP–C variants were formed by spreading lipid or lipid–protein mixtures in chloroform/methanol 3:1 (v/v) on top of a buffered sub-
phase Tris 5 mM pH 7, containing 150 mM NaCl. The compression rate was 65 cm2/min and the temperature was 25 °C.
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squeezed-out accompanied by 17±2 lipid molecules, while
rGP/SP-C and rSP-C expel 25±2 and 53±3 phospholipids per
protein molecule, respectively. Previous calculations had al-
ready suggested that the squeeze-out of native SP-C from
compressed DPPC/DPPG films is accompanied by around 10
molecules of phospholipid per mol of protein [35]. Analysis by
electron spin resonance of the stoichiometry of the interaction of
SP-C with phospholipids in bilayers allows estimating that
around 18 phospholipid molecules interacted with each SP-C
molecule at saturation [36]. Although the numbers obtained
from our isotherms may not be entirely correct without con-
sidering the protein segments that could still be inserted into
the films at high pressures, the differences observed clearly
indicate that the recombinant proteins bearing phenylalanines
remove more lipid molecules per mol of protein than the
native acylated protein. This feature can be correlated with a
potentially higher affinity of the N-terminal segment of the
recombinant proteins to maintain association with phospholi-Fig. 8. Effect of native and recombinant forms of SP-C on the removal of lipid/
protein material from highly compressed interfacial films. Percent of DPPC/
DPPG film area at 60 mN/m reduced by the presence of native porcine SP-C
(closed circles), rGP/SP-C (open circles) or rSP-C (open squares), has been
plotted versus the proportion of protein in the films (mol/mol).pids, compared with the natural SP-C, which could be also
responsible for the observed higher ability to promote interfacial
adsorption of phospholipids.
4. Discussion
The production of a recombinant SP-C has been a chal-
lenging task since the revealing of its importance in the late 80s.
The extreme hydrophobicity and its tendency to aggregate make
this protein very difficult to manipulate and many different
approaches have been taken in order to circumvent these
features. Synthetic peptides [12,28,37] and peptoids [38]
mimicking the essential structural features of SP-C have been
tested to enhance the surface-active properties of surfactant
formulations composed of synthetic phospholipids, being in all
cases less effective than the native (animal-extracted) SP-C.
Concerning the recombinant expression of the protein, efforts
have been made both for a eukaryotic baculovirus expression
system [39] and using bacterial cultures [15,33]. We decided to
employ a prokaryotic system in order to obtain SP-C in large
quantities, since bacteria are to date the best large-scale protein-
producing organism. Compared to the previously published
rSP-C expressed in Escherichia coli as a fusion to the N-
terminal portion of bacterial chloramphenicol acetyl transferase,
our strategy results more protective of the α-helical conforma-
tion necessary for optimal surface activity. This is probably
because our method does not involve resolubilisation of the
protein from inclusion bodies and exposure to polar solvents
during RP-HPLC [15]. In addition, the use of the nuclease A
(SN) as a fusion partner provides several advantages (reviewed
in [40]) for high-level heterologous expression of integral
membrane proteins at full-length. For instance, the three-
dimensional structure of SN shows numerous basic residues
exposed to the solvent [41], therefore precluding aggregation of
fusion proteins and becoming a versatile system for membrane
protein over-expression.
We expressed a modified sequence of human SP-C, which
bears two phenylalanines instead of palmitoylated cysteines,
inspired by the native sequence of SP-C from dog and mink
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debate. It is evident that SP-C maintains its function in the
presence of one phenylalanine instead of a palmitic chain, as in
the case of dog and mink SP-Cs, and the possibility remains
that this particular amino acid can mimic at least partially the
role of palmitic chains. The fact that this mutant variant has
been successfully used both in vitro and in animal experiments
supports the idea that it could be a functional equivalent to the
natural SP-C [18]. Our interfacial adsorption measurements
together with compression isotherms suggest that, at least for
the bilayer–monolayer conversions, these modified SP-C
versions could have superior properties than the native SP-C
purified from animal lungs. The compression isotherms of
phospholipid films containing increasing proportions of protein
indicate that the recombinant versions of SP-C expel more
phospholipid molecules from the interface than the native SP-
C, when the lipid–peptide films are compressed beyond the
collapse pressure of the protein. These results suggest that the
aromatic residues included into the N-terminal region of the
recombinant forms may either increase the affinity of the
protein to associate with phospholipids or promote a more
appropriate conformation of this region to accommodate a
higher number of lipid molecules. Additionally, our production
procedure, which maintains the structural integrity of the
recombinant SP-C forms, may preserve better its activity in
quantitative terms, compared to the delipidation and purifica-
tion procedure of native SP-C from animal lungs. The role of
SP-C in vivo has been mostly discussed in connection to the
protein-mediated stability of the interfacial surface active film
at end-expiration, and not much as promoting interfacial
adsorption, an activity which is better performed by SP-B [1].
However, there are strong indications suggesting that a Phe-
containing rSP-C version has enough surface activity to be
used as the only protein component of a therapeutic surfactant
preparation [15,17]. The N-terminal segment of SP-C has been
revealed as a very dynamic structural motif [42], which is able
to interact and perturb the phospholipid packing of phospho-
lipid bilayers and monolayers [43]. Acylation of this segment
may be especially important to maintain association of the
lipid/protein structures squeezed-out from the compressed
films at end-expiration with the interface [44]. In native
surfactant complexes, efficient bilayer–monolayer (during
adsorption) and monolayer–bilayer (during compression)
conversions are ensured by the presence of SP-B. A high
affinity of the protein to associate with the interface has been
recently shown to be a crucial determinant for the SP-B
activity, this association being critically dependent on the
presence of aromatic residues at the N-terminal segment of the
protein [45]. It is thus reasonable to expect that in the absence
of SP-B, SP-C variants with enhanced affinity for the interface
may show enough activity to promote bilayer–monolayer
transitions and serve as the only additive needed for efficient
therapeutic surfactant formulations. Further biophysical studies
of the surface behaviour of these and other variants are
ongoing and will allow the establishment of their potential as
SP-C (or SP-B) mimics, as well as the determination of critical
structure–function motifs.The protocol presented here is a combination of a common
strategy for over-expression of integral membrane proteins and
the organic extraction used for native SP-C isolation from
animal pulmonary lavages. This purification scheme may also
be used for obtaining other highly hydrophobic proteins. The
flexibility for creating mutants of the SP-C, aiming to specific
structural or functional studies, will greatly improve our under-
standing of the role of this protein in the LS, as well as opti-
mising current replacement preparations for respiratory
diseases. Further biophysical studies are in progress in order
to explore the full potential of these and new SP-C variants for
surfactant therapy.
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